AmyPore

AmyPore is a biotechnology startup with a compelling mission - "New target, new paradigm, new strategy that addresses the root cause of Alzheimer, Parkinson, and other proteinopathies." The company was founded in 2018 in France and is led by Pr. Nouara Yahi and Pr. Jacques Fantini from the University of Aix-Marseillle and the Institut Universitaire de France. AmyPore's core expertise lies in molecular neurosciences, as evidenced by their groundbreaking discovery of AmyP53, a patented nontoxic molecule designed to combat the common mechanism of neurotoxicity shared by Alzheimer's and Parkinson's diseases. From a technological standpoint, AmyPore leverages a pioneering computational discovery platform, high performance lipid-protein and protein-protein binding technology, and an ultrasensitive Ca2+ amyloid pore reporting assay. These innovative tools enable the company to identify and neutralize novel targets that control pathologic protein misfolding, setting them apart as a key player in the fight against neurodegenerative diseases. In terms of investments, AmyPore received Non Equity Assistance from Incubateur Impulse on 03 April 2019. This funding injection is expected to support the development of a nasal spray for treating patients with Alzheimer's or Parkinson's diseases. Additionally, the company is actively working on a pipeline of therapeutic peptides capable of preventing the formation of oligomers implicated in the development and progression of degenerative proteinopathies, including amyotrophic lateral sclerosis (ALS) and type 2 diabetes. With its innovative approach and strategic focus on addressing the root causes of debilitating neurological conditions, AmyPore is poised to make a significant impact in the biotechnology and healthcare industries.